Research and Markets: Substance Abuse - Poisoning Drug Pipeline Report
Posted on: Wednesday, 11 July 2007, 12:04 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c62417) has announced the addition of Substance Abuse - Poisoning Drug Pipeline Report to their offering.
"Substance Abuse - Poisoning Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of poisoning drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Content Outline:
RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
Poisoning Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects
--Legend
--Top 20 companies in late stage Poisoning Projects
--Top 20 companies in early stage Poisoning Projects
Full Pipeline View
--Pending Approval Pipeline View
For more information visit http://www.researchandmarkets.com/reports/c62417
Source: Life Science Analytics
Source: Business Wire
Related Articles
- BuildingGreen Publishing Company Names Thermafiber(R) Mineral Wool Insulation a Top-10 Product
- Kidneys And Genito-Urinary System - Benign Prostatic Hyperplasia Drug Pipeline Report Provides Detail On The Top 20 Companies With Products In The Early And Late Stage Of Development
- Kidneys and Genito-Urinary System - Hyperphosphatemia Drug Pipeline Report Provides Detail on the Top 20 Companies With Products in the Early and Late Stage of Development
- Infections -- Malaria Drug Pipeline Report Provides Detail on the Top 20 Companies With Products in the Early and Late Stage of Development
- Kidneys and Genito-Urinary System - Overactive Bladder Drug Pipeline Report Provides Detail on the Top 20 Companies With Products in the Early and Late Stage of Development
- Kidneys and Genito-Urinary System - Urinary Incontinence Drug Pipeline Report - Study the Top 20 Companies in Early and Late Stage of Development
- Metabolic Endocrinology - Diabetic Neuropathy Drug Pipeline Report - Study the Top 20 Companies With Products in the Early and Late Stage of Development
- Infections - Hepatitis C Drug Pipeline Report Provides Detail on Top 20 Companies With Products in the Early and Late Stage of Development
- View Details on the Top 20 Companies With Products in the Early Stage of Development for Non-Small-Cell Lung Cancer, Lung Cancer or Small Cell Lung Cancer
- Endovasc Outlines Plans for Continued Development of Liprostin; Promising Phase II Clinical Trial Results Warrant Further Trials
User Comments (0)

RSS Feeds